Melt Pharmaceuticals

Melt Pharmaceuticals is thrilled to share an exciting milestone for our lead product candidate, MELT-300! The topline results from our MELT-300 pivotal Phase 3 study are in—and they’re overwhelmingly positive! MELT-300, our innovative, needle- and opioid-free sedation solution for cataract surgery, has shown robust results that reinforce our belief in its potential to transform procedural sedation. If approved, MELT-300 could provide a safe, effective, and non-IV alternative to current cataract surgery sedation protocols that often include opioids. These Phase 3 data confirms our mission and belief that MELT-300, if approved, could elevate the standard of care for procedural sedation, starting with cataract surgery and eventually expanding the potential use to other medical specialties through lifecycle management. A heartfelt THANK YOU to everyone who contributed to this pivotal study: ophthalmologists, optometrists, anesthesiologists, CRNAs, staff, and—most importantly—the patients. Your contributions have brought us one step closer to our goal of revolutionizing procedural sedation. #eyecare #eyecareprofessionals #ophthalmologists #healthcare #pharmaceuticals #MELT300 #ProceduralSedation #Innovation #cataractsurgery https://lnkd.in/eUA_-9tt

Melt Pharmaceuticals is thrilled to share an exciting milestone for our lead product candidate, MELT-300! The topline results from our MELT-300 pivotal Phase 3 study are in—and they’re overwhelmingly positive! MELT-300, our innovative, needle- and opioid-free sedation solution for cataract surgery, has shown robust results that reinforce our belief in its potential to transform procedural sedation. If approved, MELT-300 could provide a safe, effective, and non-IV alternative to current cataract surgery sedation protocols that often include opioids. These Phase 3 data confirms our mission and belief that MELT-300, if approved, could elevate the standard of care for procedural sedation, starting with cataract surgery and eventually expanding the potential use to other medical specialties through lifecycle management. A heartfelt THANK YOU to everyone who contributed to this pivotal study: ophthalmologists, optometrists, anesthesiologists, CRNAs, staff, and—most importantly—the patients. Your contributions have brought us one step closer to our goal of revolutionizing procedural sedation. #eyecare #eyecareprofessionals #ophthalmologists #healthcare #pharmaceuticals #MELT300 #ProceduralSedation #Innovation #cataractsurgery https://lnkd.in/eUA_-9tt

Melt Pharmaceuticals is proud to announce the last dosing in our pivotal Phase 3 clinical study for MELT-300, our innovative lead product candidate for needle-free, opioid-free procedural sedation in cataract surgery and the FDA’s agreement with our Phase 3 Special Protocol Assessment. These milestones are significant steps toward our goal to revolutionize the standard of care in procedural sedation. A heartfelt thank you to all the investigators, healthcare professionals, and patients who have helped us reach these milestones. #eyecare #eyecareprofessionals #ophthalmologists #healthcare #pharmaceuticals #MELT300 #ProceduralSedation #Innovation #cataractsurgery https://lnkd.in/e525Hezn

Melt Pharmaceuticals is excited to announce that the first patient has been dosed in its pivotal Phase 3 program for MELT-300. A topline readout is expected in the fourth quarter of 2024. The Company believes that MELT-300, a non-IV, non-opioid tablet, could revolutionize procedural sedation while enhancing the patient’s experience in all sites of care by offering greater comfort without a needle stick and by reducing exposure to opioids. #eyecare #eyecareprofessionals #ophthalmologists #healthcare #pharmaceuticals #MELT-300 #ProceduralSedation #Innovation #cataractsurgery https://lnkd.in/ecWhWHKC

Melt Pharmaceuticals closes funding for MELT-300 Phase 3 program, which commenced in first quarter of 2024. First patient dosing expected in second quarter of 2024 with a topline readout expected in the fourth quarter of 2024. #eyecare?#eyecareprofessionals?#ophthalmologists?#cataractsurgery?#healthcare?#healthcareprofessions?#pharmaceuticals #proceduralsedation #non-IV #non-opioid https://lnkd.in/emGNg-W2

Melt Pharmaceuticals provides corporate update, including progress on its non-IV, non-opioid MELT-300 product candidate, paving the way for commencement of its MELT-300 Phase 3 program activities. #eyecare?#eyecareprofessionals?#ophthalmologists?#cataractsurgery?#healthcare?#healthcareprofessions?#pharmaceuticals https://lnkd.in/eTD842U4